Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative therapies work by mimicking the natural actions of GLP-1, a hormone released by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these substances boost insulin production and inhibit glucago

The management of diabetes has become with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant traction. These medications offer promising mechanisms for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel c